nach oben

Forensic Toxicology

Erschienen in:

07.02.2018 | Original Article

MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB₁- and CB₂-receptor-dependent manner in conscious rats

verfasst von: Hideyuki Maeda, Erika Nagashima, Yukiko K. Hayashi, Ruri Kikura-Hanajiri, Ken-ichi Yoshida

Erschienen in: Forensic Toxicology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

MDMB-CHMICA, a new synthetic cannabinoid (SC), has become prevalent since 2014 as an ingredient of recreational drugs. Reports on intoxication due to the drug have been increasing, which show diverse cardiovascular, psychiatric, and neuronal symptoms. Reports on sudden death and accidental death related to psychiatric disorders in MDMB-CHMICA intoxication have also increased, but the underlying mechanisms are largely unknown.

Methods

As there has been no experimental study on the drug, we investigated the effects of peripheral injection of MDMB-CHMICA in conscious rats.

Results

MDMB-CHMICA induced rapid bradycardia and a slow pressor response. Cardiovascular responses to other SCs have been shown to be inhibited only by cannabinoid receptor-1 (CB₁)-antagonists. However, the MDMB-CHMICA-induced bradycardia was inhibited not only by a CB₁-antagonist, AM281, but also by a CB₂-antagonist, AM630. Unlike other SCs, MDMB-CHMICA induced a gradual increase in mean blood pressure, which was marginally enhanced by the CB₁- and CB₂- antagonists. For the first time, we demonstrated that MDMB-CHMICA induces a thrashing hypermobile behavior in a CB₁- and CB₂-receptor-dependent manner, following catalepsy-like hypomobile behavior.

Conclusions

This unexpected response to MDMB-CHMICA may help explain the mechanisms underlying the sudden deaths and accidents associated with its use.

Nur mit Berechtigung zugänglich

WHO (2016) MDMB-CHMICA, critical review report, agenda item 4.9. http://www.who.int/medicines/access/controlled-substances/4.9_MDMB-CHMICA_CritReview.pdf. Accessed 14 Feb 2017

EMCDDA (2016) EMCDDA-Europol Joint Report on a new psychoactive substance: methyl 2-[[1-(cyclohexylmethyl) indol-3-carbonyl] amino]-3, 3-dimethylbutanoate (MDMB-CHMICA). https://doi.org/10.2810/08132

Hill SL, Najafi J, Dunn M, Acheampong P, Kamour A, Grundlingh J, Blain PG, Thomas SHL (2016) Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol 54:638–643. https://doi.org/10.1080/15563650.2016.1190980 CrossRef

Seywright A, Torrance HJ, Wylie FM, McKeown DA, Lowe DJ, Stevenson R (2016) Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clin Toxicol 54:632–637. https://doi.org/10.1080/15563650.2016.1186805 CrossRef

Westin AA, Frost J, Brede WR, Gundersen POM, Einvik S, Aarset H, Slørdal L (2016) Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol 40:86–87. https://doi.org/10.1093/jkt/bkv110 PubMedCrossRef

Adamowicz P (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 261:e5–e10. https://doi.org/10.1016/j.forsciint.2016.02.024 CrossRefPubMed

Randall MD, Kendall DA, O’Sullivan S (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142:20–26. https://doi.org/10.1038/sj.bjp.0705725 CrossRefPubMedPubMedCentral

Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7:1241–1254. https://doi.org/10.1021/acschemneuro.6b00137 CrossRefPubMed

Niederhoffer N, Schmid K, Szabo B (2003) The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 367:434–443. https://doi.org/10.1007/s0010-003-0755-y CrossRefPubMed

10.

Gardiner SM, March JE, Kemp PA, Bennett T (2002) Influence of the CB₁ receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 136:581–587. https://doi.org/10.1038/sj.bjp.0704750 CrossRefPubMedPubMedCentral

11.

Niederhoffer N, Szabo B (2000) Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 294:707–713. http://jpet.aspetjournals.org/content/jpet/294/2/707.fll.pdf

12.

Niederhoffer N, Szabo B (1999) Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126:457–466. https://doi.org/10.1038/sj.bjp.0702337 CrossRefPubMedPubMedCentral

13.

Gardiner SM, March JE, Kemp PA, Bennett T (2001) Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br J Pharmacol 133:445–453. https://doi.org/10.1038/sj.bjp.0704100 CrossRefPubMedPubMedCentral

14.

AlSuleimani YM, Hiley CR (2013) Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol 702:1–11. https://doi.org/10.1016/j.ejphar.2013.01.006 CrossRefPubMed

15.

Bonz A, Laser M, Küllmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA (2003) Cannabinoids acting on CB₁ receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41:657–664 (PMID:12658069) CrossRefPubMed

16.

Krylatov AV, Maslov LN, Ermakov SY, Barzakh EI, Lasukova OV, Crawford D, Ghadessy R, Serebrov VY (2006) Negative chronotropic effect of cannabinoids and their water-soluble emulsion is related to activation of cardiac CB1 receptors. Bull Exp Biol Med 142:450–453. https://doi.org/10.1007/s10517-006-0389-4 CrossRefPubMed

17.

Gonzalez C, Herradon E, Abalo R, Vera G, Perez-Nievas BG, Leza JC, Martin MI, Lopez-Miranda V (2011) Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in zucker diabetic fatty rats: role of CB₂ receptors and iNOS/eNOS. Diabetes Metab Res Rev 27:331–340. https://doi.org/10.1002/dmrr.1176 CrossRefPubMed

18.

Spaderna M, Addy PH, D’Souza DC (2013) Spicing things up: synthetic cannabinoids. Psychopharmacology 228:525–540. https://doi.org/10.1007/s00213-013-3188-4 CrossRefPubMedPubMedCentral

19.

Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K, Takasaki K, Katsurabayashi S, Iwasaki K, Uchida N, Egawa T, Kitamura Y, Nishimura R, Fujiwara M (2008) Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 151:320–328. https://doi.org/10.1016/j.neuroscience.2007.10.026 CrossRefPubMed

20.

McLaughlin PJ, Lu D, Winston KM, Thakur G, Swezey LA, Makriyannis A, Salamone JD (2005) Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol Biochem Behav 81:78–88. https://doi.org/10.1016/j.pbb.2005.02.005 CrossRefPubMed

21.

Simmons JR, Skinner CG, Williams J, Kang CS, Schwartz MD, Wills BK (2011) Intoxication from smoking “spice”. Ann Emerg Med 57:187–188. https://doi.org/10.1016/j.annemergmed.2010.08.039 CrossRefPubMed

Titel: MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB1- and CB2-receptor-dependent manner in conscious rats
verfasst von: Hideyuki Maeda
Erika Nagashima
Yukiko K. Hayashi
Ruri Kikura-Hanajiri
Ken-ichi Yoshida
Publikationsdatum: 07.02.2018
Verlag: Springer Japan
Erschienen in: Forensic Toxicology / Ausgabe 2/2018
Print ISSN: 1860-8965
Elektronische ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-018-0405-1

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB₁- and CB₂-receptor-dependent manner in conscious rats

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Identifying exposures to ribosome-inactivating proteins in blood samples: amplification of ricin-induced ribosomal damage products enables sensitive detection of active toxin and circulating depurinated 28S rRNA

Pentobarbital use in a decomposed suicide

Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry

Differentiation of AB-FUBINACA and its five positional isomers using liquid chromatography–electrospray ionization-linear ion trap mass spectrometry and triple quadrupole mass spectrometry

Effects of the new generation α-pyrrolidinophenones on spontaneous locomotor activities in mice, and on extracellular dopamine and serotonin levels in the mouse striatum

Detection of pyrovalerone as a possible synthetic by-product of 4′-methyl-α-pyrrolidinohexanophenone and 4-methyl-α-ethylaminopentiophenone in illicit drug products

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie